CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Other Events
Item 8.01
| Press Release issued by CareDx, Inc., dated April25, 2019. |
CareDx, Inc. Exhibit
EX-99.1 2 d735922dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CareDx Agrees to Acquire OTTR Complete Transplant Management OTTR acquisition will enable EMR integrations at transplant centers and longitudinal patient data management BRISBANE,…
To view the full exhibit click here
About CAREDX, INC. (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
